BMC Public Health (Apr 2020)

Drinking patterns and hydration biomarkers among young adults with different levels of habitual total drinking fluids intake in Baoding, Hebei Province, China: a cross-sectional study

  • Jianfen Zhang,
  • Na Zhang,
  • Yan Wang,
  • Shuxin Liang,
  • Shufang Liu,
  • Songming Du,
  • Yifan Xu,
  • Hairong He,
  • Hao Cai,
  • Guansheng Ma

DOI
https://doi.org/10.1186/s12889-020-08558-z
Journal volume & issue
Vol. 20, no. 1
pp. 1 – 11

Abstract

Read online

Abstract Background The purposes were to investigate the drinking patterns and hydration biomarkers among young adults with different levels of habitual total drinking fluids intake. Methods A cross-sectional study was conducted among 159 young adults aged 18–23 years in Baoding, China. Total drinking fluids and water from food were assessed by 7-day 24-h fluid intake questionnaire and duplicate portion method, respectively. The osmolality and electrolyte concentrations of the 24 h urine and fasting blood samples were tested. Differences in LD1 (low drinker), LD2, LD3 and HD (high drinker) groups, stratified according to the quartiles of total drinking fluids, were compared using one-way ANOVA, Kruskal-Wallis H test and chi-square test. Results A total of 156 participants (80 males and 76 females) completed the study. HD group had greater amounts of TWI (Total Water Intake), water from food, higher and lower contributions of total drinking fluids and water from food to TWI, respectively, than LD1, LD2 and LD3 groups (p 0.05). The osmolality of urine was 59–143 mOsm/kg higher in LD1 than that in LD2, LD3 and HD group (p 0.05), with the exception of higher concentration of Mg in LD3 and HD groups than that in LD1 and LD2 groups (p < 0.05). Conclusions Participants with higher total drinking fluids had better drinking pattern and hydration status. Interventions should be undertaken to advise adults to have adequate total drinking fluids, in order to keep in optimal hydration status. Trial registration The registration number was ChiCTR-ROC-17010320 , which was registered on the Chinese clinical trial registry.

Keywords